{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:14:14Z","timestamp":1793229254264,"version":"4.5.0"},"reference-count":32,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"unspecified","delay-in-days":4764,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. psychiatr."],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S0924933800244945_abs1\" sec-type=\"other\"><jats:title>Purpose<\/jats:title><jats:p>The ZEISIG study (Ziprasidone Experience in Schizophrenia in Germany\/Austria) investigated the effectiveness of ziprasidone as measured by discontinuation rates and mean changes of the BPRS total. Secondary objectives included quality of life, subjective well-being, tolerability, and safety.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800244945_abs2\" sec-type=\"methods\"><jats:title>Subjects and methods<\/jats:title><jats:p>Two hundred and seventy-six subjects with schizophrenia and schizoaffective disorder were treated within an open-label, 12-week, prospective, flexible-dose observational trial of ziprasidone (40\u2013160 mg\/day). Baseline and outcome assessments mainly included Brief Psychiatric Rating Scale (BPRS), Clinical Global Impressions Scale (CGI), Short-Form 12 (SF-12), and Subjective Well-being under Neuroleptic treatment (SWN-K).<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800244945_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Study discontinuation due to any cause was evident in 58% of subjects, most of them within the first 4 weeks after study initiation. In study completers, ziprasidone was associated with improvements in BPRS total (44.8 to 33.6; <jats:italic>p<\/jats:italic> &lt; 0.001), CGI, SF-12, and SWN-K total scores (80.5 to 89.5). Ziprasidone was related to reduction of weight, fasting glucose, and serum lipids. No cardiovascular adverse event or significant increase of the QTc interval was observed.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800244945_abs4\" sec-type=\"conclusions\"><jats:title>Discussion and conclusion<\/jats:title><jats:p>Approximately 60% of subjects discontinued ziprasidone prematurely, probably related to an initial and overall underdose. The present study confirmed previous tolerability and safety data of ziprasidone as well as results of its effectiveness. Independent from reason to switch, previous antipsychotic class, and severity of illness at baseline, the recommended starting dose of 80 mg\/day as well as the maximum treatment dose of 160 mg\/day may not be sufficient for a selected subgroup of patients.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.eurpsy.2006.06.004","type":"journal-article","created":{"date-parts":[[2006,11,30]],"date-time":"2006-11-30T15:10:51Z","timestamp":1164899451000},"page":"195-202","source":"Crossref","is-referenced-by-count":20,"title":["Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: Results of a multi-centre observational trial"],"prefix":"10.1017","volume":"22","author":[{"given":"Duerten","family":"Kudla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Domin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Naber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"S0924933800244945_bib29","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.161.10.1837"},{"key":"S0924933800244945_bib22","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.01.013"},{"key":"S0924933800244945_bib21","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.5.818"},{"key":"S0924933800244945_bib17","doi-asserted-by":"publisher","DOI":"10.1097\/00131746-200407000-00003"},{"key":"S0924933800244945_bib16","article-title":"Remission of severely impaired subjective well-being in 727 patients with schizophrenia treated with amisulpride","author":"Lambert","journal-title":"Acta Psychiatrica Scand"},{"key":"S0924933800244945_bib15","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-873155"},{"key":"S0924933800244945_bib13","first-page":"11","article-title":"Schizophrenia and comorbid metabolic disorders","volume":"66","author":"Henderson","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"S0924933800244945_bib18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"S0924933800244945_bib11","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2003.07.009"},{"key":"S0924933800244945_bib8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.4088\/JCP.v66n0619","article-title":"Advancing the treatment of people with mental illness: a call to action in the management of metabolic issues","volume":"66","author":"Franciosi","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"S0924933800244945_bib6","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0415"},{"key":"S0924933800244945_bib5","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-2082-5"},{"key":"S0924933800244945_bib3","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200209000-00001"},{"key":"S0924933800244945_bib2","first-page":"249","volume-title":"American Psychiatric Association practice guidelines for the treatment of psychiatric disorders. Compendium 2004","year":"2004"},{"key":"S0924933800244945_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-1614.2005.01516.x","article-title":"Royal Australian and\u00a0New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders","volume":"39","author":"McGorry","year":"2005","journal-title":"Aust N Z J Psychiatry"},{"key":"S0924933800244945_bib1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n1207"},{"key":"S0924933800244945_bib7","first-page":"596","article-title":"American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"Clark","year":"2004","journal-title":"Diabetes Care"},{"key":"S0924933800244945_bib10","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000104913.75206.62"},{"key":"S0924933800244945_bib30","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199603000-00003"},{"key":"S0924933800244945_bib4","first-page":"CD001945","article-title":"Ziprasidone for schizophrenia and severe mental illness","volume":"4","author":"Bagnall","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"S0924933800244945_bib26","first-page":"157","volume-title":"EDCEU assessment battery","author":"Overall","year":"1976"},{"key":"S0924933800244945_bib14","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.01.009"},{"key":"S0924933800244945_bib12","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.2.337"},{"key":"S0924933800244945_bib27","doi-asserted-by":"publisher","DOI":"10.1097\/01.yco.0000186017.72973.8c"},{"key":"S0924933800244945_bib32","first-page":"13","article-title":"Schizophrenia and obesity: impact of antipsychotic medications","volume":"65","author":"Wirshing","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"S0924933800244945_bib19","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900009342"},{"key":"S0924933800244945_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.yic.0000182121.59296.70","article-title":"Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study","volume":"21","author":"Olie","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"S0924933800244945_bib31","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0514"},{"key":"S0924933800244945_bib9","first-page":"218","volume-title":"ECDEU assessment manual for psychopharmacology, revised. US Dept Health, Education, and Welfare publication (ADM) 76-338","author":"Guy","year":"1976"},{"key":"S0924933800244945_bib23","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(00)00166-3"},{"key":"S0924933800244945_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852900019842","article-title":"From clinical research to clinical practice: a 4-year review of ziprasidone","volume":"10","author":"Nemeroff","year":"2005","journal-title":"CNS Spectr"},{"key":"S0924933800244945_bib28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933806001325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933806001325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933800244945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T09:35:05Z","timestamp":1587116105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933800244945\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0924933800244945"],"URL":"https:\/\/doi.org\/10.1016\/j.eurpsy.2006.06.004","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}